WRBY

WARBY PARKER INC

Healthcare | Mid Cap

$0.03

EPS Forecast

$244.8

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Warby Parker’s Q3 2026: A Clearer View on Growth, Margin, and the Smart Glasses Horizon

Ticker: WRBY. In this quarter, investors will scan for EPS and EPS consensus clues, compare revenue forecast hints, and look for any earnings surprise versus Street expectations. Warby Parker Inc. reports its third quarter results for the period ended September 30, 2026, offering a snapshot of a brand pushing deeper into care services and a rumored leap into Intelligent Eyewear.

Overview of the Quarter

Warby Parker delivered a revenue bump to $244.7 million, up 10.4% year over year, with gross margin marching to 54.4%. The company added 12 net new stores in the quarter, ending the period with 364 stores, a sign the retail footprint continues to be a meaningful driver of top-line growth.

On the customer front, Active Customers rose 3.0% to 2.74 million on a trailing 12-month basis, while Average Revenue per Customer (ARPC) climbed to $342, up 6.7% year over year. The line items suggest a combination of traffic growth and product mix that leans into higher-value offerings, or at least a healthy price realization.

Net income came in at $5.6 million, with Adjusted EBITDA of $28.6 million. The press release notes Adjusted Gross Profit of $133.6 million (54.6% of revenue) against a reported gross profit of $133.2 million (54.4%), pointing to a familiar pattern in tech-enabled retail where adjustments drive the “operating” view of profitability.

What the Numbers Highlight

  • Revenue growth is real, but margins remain the key pressure point—the company explicitly calls out leverage in glasses and other costs as drivers of gross margin dynamics, while occupancy costs and fixed costs dampen the overall margin expansion.
  • SG&A totaled $129.6 million, up $13.2 million from the prior year. As a percentage of revenue, SG&A rose by 50 basis points, largely due to retail compensation and higher technology expenses, with some relief from leaner marketing spend as a share of revenue.
  • Adjusted SG&A stood at $120.8 million, framing the company’s focus on what it deems core operating profitability, even as the GAAP line shows a modest net income result.
  • The “Third Quarter 2026 Year-Over-Year” section underscores ongoing investments in care offerings (Warby Parker Care) and expansion, including the anticipated introduction of Intelligent Eyewear later in the year, with pre-orders beginning November 12 and holiday deliveries in view.

Intelligent Eyewear: The Next Frontier or a Just-Okay Beta?

The company signals a strategic bet beyond frames and lenses: Intelligent Eyewear. Management highlighted that pre-orders kick off soon, with a broader rollout to follow. The market will want to see how this product category affects both revenue mix and gross margin, especially in a consumer environment where optics pricing can be sticky and component costs volatile.

For peers in the sector, the move toward smart eyewear represents a potential revenue forecast upgrade risk if early demand proves durable and if supply chains accommodate premium hardware without eroding margins. In a year where few DTC players have nailed hardware-based consumer devices at scale, Warby Parker’s execution in this space could become a differentiator—or at least a talking point on conference calls.

Care Programs and Services as Growth Levers

The ongoing rollout of Warby Parker Care and related services suggests a deliberate shift from pure product sales to a broader services framework. This has the potential to lift customer lifetime value, given expanding access to exams and insurance-related offerings, and to improve retention as the care ecosystem deepens.

What This Could Mean for the Company and Its Peers

From a strategic standpoint, the Q3 results reinforce a few themes the sector will monitor closely:

  • Top-line momentum appears solid, supported by store network expansion and ARPU uplift. The question for investors becomes how much of this revenue growth translates into sustainable earnings, given ongoing investments in SG&A and technology.
  • Gross margin dynamics matter. With 54.4% gross margin and modest adjustments, investors will watch for margin resilience as the company scales its care offerings and new product categories.
  • Channel and product mix risk. The success or failure of Intelligent Eyewear and care services will influence short-term profitability and long-term leverage. If the new product categories gain traction, revenue forecasts could move higher; if not, the focus remains on cost discipline and operational efficiency.
  • Competition pressure mounts in a crowded, premium eyewear space. Warby Parker’s dual push—retail footprint and digital adoption—needs to maintain a balance between growth and profitability to sustain investor confidence.

Analyst Lens: EPS, EPS Consensus, and Market Calibration

Even with a $5.6 million net income, the absence of an explicit EPS figure in the release invites a quick exercise: how does this translate to EPS consensus given the company’s share count and potential non-GAAP adjustments? Investors will likely parse whether the headline numbers imply a positive EPS surprise, a modest miss, or something in between once per-share metrics are reconciled. In the near term, the stock’s reaction will hinge on how convincingly Warby Parker can translate revenue growth into durable earnings power—through gross margin expansion, expense discipline, and the uptake of Care and Intelligent Eyewear.

Closing Thoughts

Warby Parker is wrapping up a quarter that showcases disciplined top-line growth, a measured margin story, and an ambitious product roadmap. The Intelligent Eyewear launch will be a focal point for the rest of the year, shaping not only Warby Parker’s own trajectory but also serving as a signal for peers weighing investments in consumer hardware and healthcare-enabled services.

For investors, the enduring questions are: Will the Care program unlock higher customer lifetime value without bloating costs? Will Intelligent Eyewear deliver meaningful incremental revenue, or will it become a case study in early-stage hardware risk? And how will EPS and revenue forecast revisions adjust as the company builds out its multi-pronged growth engine?

Disclaimer: This article discusses a corporate earnings release and provides forward-looking interpretation based on reported data. Ticker WRBY, EPS, earnings surprise, EPS consensus, and revenue forecast references are included to frame the narrative without guaranteeing future results.